ArticleMicroorganisms2023
Celecoxib-Loaded Cubosomal Nanoparticles as a Therapeutic Approach for
Article in Microorganisms, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 19 citations in OpenAlex.
- pH-Responsive Chitosan-Coated Spanlastic Nanovesicles for Enhanced Lung-Targeted Delivery of Brilliant Blue G in Acute Lung Injury.AAPS PharmSciTech · 2026Article
- Biotransformation-guided production of quinalizarin as an antibacterial agent against Acinetobacter baumannii.Applied microbiology and biotechnology · 2026Article
- Preclinical evaluation of repositioned non-antibiotic agents against Staphylococcus aureus: a network meta-analysis of survival outcomes.World journal of microbiology & biotechnology · 2025Article
- Innovative nanocarriers in arthritis therapy: the role of herbal cubosomes.Inflammopharmacology · 2025Review
- Innovative pH-responsive alginate-coated rosuvastatin-loaded chitosan nanoparticles: a targeted approach to inhibiting HMGB1-activated RAGE/TLR4-NFκB signaling in colonic inflammation in rats.Frontiers in pharmacology · 2025Article
- Neuroprotective efficiency of celecoxib vesicular bilosomes for the management of lipopolysaccharide-induced Alzheimer in mice employing 2Inflammopharmacology · 2024Article
- Arthrospira maxima and biosynthesized zinc oxide nanoparticles as antibacterials against carbapenem-resistant Klebsiella pneumoniae and Acinetobacter baumannii: a review article.Microbial cell factories · 2024Review
- Advancing therapeutic efficacy: nanovesicular delivery systems for medicinal plant-based therapeutics.Naunyn-Schmiedeberg's archives of pharmacology · 2024Review
- Cubosomal nanoformulation increaseTherapeutic delivery · 2024Article
- Hedgehog signaling is a promising target for the treatment of hepatic fibrogenesis: a new management strategy using itraconazole-loaded nanoparticles.Frontiers in pharmacology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is a great need for novel approaches to treating bacterial infections, due to the vast dissemination of resistance among pathogenic bacteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.